2013 ASPIRE Hemophilia Research Awards
As competition for research funding increases, the ASPIRE HEMOPHILIA program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research careers in Hemophilia A & B.
Mission
The mission of the ASPIRE Program is as follows.
• To support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis and treatment of hemophilia.
•To support academic research as well as the career development of promising young and established scientists.
Basic science and clinical research continue to advance our knowledge and understanding of Hemophilia A and Hemophilia B. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available.
The ASPIRE HEMOPHILIA program is designed to support basic science and clinical research in Hemophilia pathogenesis, host response and clinical outcomes in Hemophilia A and Hemophilia as well as translation of the resulting knowledge to bridge the gap between bench and bedside.
It is hoped that the results will lead to a better understanding of disease mechanisms and treatment options to enhance the clinical care of patients with Hemophilia A or Hemophilia B
Areas of Focus: Hemophilia A and Hemophilia B
Pfizer will support competitive grant programs which address one of the following areas in Hemophilia A and/or Hemophilia B.
Available Awards
Application is open to US investigators. Selection of research proposals will be performed by an independent, external expert panel comprised of nationally known academic clinicians. Project duration should be 1-2 years and should be approximately $125,000/year, inclusive of overhead costs.
To be eligible for an ASPIRE Hemophilia award, applicants must:
• have a doctoral degree (MD, PhD, PharmD, or equivalent);
• reside and practice in the United States.
Deadline for Application
• Applications must be received by Monday, May 20, 2013, 11:59 PM Eastern Daylight Time
• Addenda, supplemental materials, changes, or updates will not be accepted after the deadline
• Award decisions will be made in July 2013
• Successful applicants will be notified in July/August 2013
• The final study results or an interim progress report is expected on or before December 31, 2014
How to Apply
Applications should be submitted through the online submission website.
Questions
questions.aspireresearch-HEMOPHILIA@pfizer.com
